News

B Braun’s distribution territory will be world-wide, excluding the US, Canada, Mexico, Japan, the Middle East, Australia, New Zealand, Greece, South Africa and China. The definitive agreement is

The main products in Stallergenes’s injectable and sublingual ranges will soon be the subject of registration applications. This partnership reportedly enables Stallergenes to meet more than 80% of

Under the terms of the agreement, the kits will be sold under both companies’ names. Kits will be shipped directly from Stemgent, and representatives from both Stemgent and

According to Quick-Med, the Nimbus is a next-generation wound care technology that is non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. Ladd Greeno,

Through the collaboration Biovitrum gains access to the proprietary technology platforms of Affibody molecules, as well as the unique albumin-binding technology for pharmaceuticals development. The agreement consists of

According to Gore, the Excluder AAA endoprosthesis device is an endovascular graft and stent combination that seals off the aneurysm and creates a new path for blood flow.

This second phase of the Absorb clinical trial will enroll approximately 80 patients at 10 centers in Europe, Australia and New Zealand, and will incorporate device enhancements designed

The patents represent the first issued for a family of applications focused in brachytherapy, said Cianna. According to the company, the Savi multi-catheter open architecture design allows for

This transfection device simplifies the delivery of DNA, RNA, and proteins into a wide range of mammalian cell types, especially difficult to transfect cells, such as many types